Phosphoric acid compound capable of resisting intestinal bacterial adhesion as well as preparation method and application of phosphoric acid compound

Abstract

The invention discloses a phosphoric acid compound capable of resisting intestinal bacterial adhesion as well as a preparation method and application of the phosphoric acid compound, and belongs to the technical field of foods and medicines. The phosphoric acid compound is prepared from an amino-rich compound, a solution containing a phosphate compound with the mass concentration being 3% or above, a solution containing a zinc compound with the mass concentration being 3% or above, glucomannan, an alkaline solution and water. The phosphoric acid compound can effectively inhibit the adhesion of bacteria to intestinal mucosa, can control the probability of intestinal bacteria invasion, reduce the occurrence probability of intestinal leakage, control chronic inflammation in the body, can solve the intestinal health problem caused by the adhesion of intestinal bacteria, and plays an important role. In order to ensure the safety of the product and not introduce reagents and substances harmful to health, the used preparation process and production process are simple and easy to industrially amplify, harmful substances are prevented from being generated in the production process, the operation is easy, and large-scale production can be realized.

Description

Technical Field

[0001] The present invention belongs to the technical field of food and medicine, and particularly relates to a phosphoric acid complex with intestinal antibacterial adhesion, a preparation method thereof, and an application thereof. Background Art

[0002] The intestine is a habitat for microorganisms. When pathogenic microorganisms in the intestine adhere to the intestinal wall, they will release more toxins, damage the intestinal mucosal barrier, and cause intestinal leakage. The first step for pathogenic bacteria to cause intestinal leakage is to adhere to the intestinal mucosa. By adhering to the intestine, they can settle down and will not be expelled from the body by intestinal peristalsis. Secondly, they invade and release toxins to damage the intestinal wall, paving the way for themselves to enter the body. Therefore, the most important and effective link to reduce the damage of pathogenic microorganisms is to prevent them from adhering to the intestinal mucosa.

[0003] For bacteria to adhere to the intestinal wall, first, they rely on the charge of bacterial membrane teichoic acid (Gram-positive bacteria) or the hydrophobic components of the outer membrane of bacteria (outer membrane proteins of Gram-negative bacteria) to contact the intestinal mucosa, narrowing the distance between the bacteria and the intestinal mucosa. Secondly, they rely on the outer membrane proteins of bacteria to have a relatively close contact and interaction with the receptors on the intestinal mucosal cells. Finally, the invasion process is initiated. Therefore, a more effective antibacterial adhesion process should be to prevent the adhesion process mediated by bacterial outer membrane proteins.

[0004] However, currently, the mechanism of antibacterial adhesion mainly achieves the goal by covering antibacterial components on the target. For the intestine, the use of antibacterial agents will affect intestinal probiotics, and long-term use will lead to bacterial drug resistance and cannot be used in the intestinal environment. The key component of bacterial adhesion is the outer membrane protein. There are significant differences in the outer membrane proteins of different pathogenic bacteria, and currently, there is no method and technology to prevent the adhesion of outer membrane proteins. Summary of the Invention

[0005] Aiming at the current lack of intestinal antibacterial adhesion materials, the first object of the present invention is to provide a preparation method of a phosphoric acid complex with intestinal antibacterial adhesion. This preparation method is easy to operate, has high production efficiency, and is suitable for large-scale production.

[0006] The second object of the present invention is to provide a phosphoric acid complex with intestinal antibacterial adhesion. This phosphoric acid complex can effectively inhibit the adhesion of bacteria to the intestinal mucosa, control the probability of intestinal bacteria invasion, reduce the incidence of intestinal leakage, control chronic inflammation in the body, solve the intestinal health problems caused by intestinal bacteria adhesion, and plays an important role.

[0007] The third object of the present invention is to provide an application of the phosphoric acid complex with intestinal antibacterial adhesion, which can be used as a product for preparing functional foods or medicines for preventing and treating intestinal health problems.

[0008] The present invention is achieved through the following technical solutions:

[0009] A preparation method of a phosphoric acid complex for intestinal anti-bacterial adhesion, comprising the following steps:

[0010] S1. Select 1-3 parts of amino-rich compounds, 0.5-2 parts of phosphate compounds, and 0.1-0.5 part of glucomannan, mix them together and dissolve in water, stir and keep warm at 70-95°C for not less than 30 minutes to obtain a mixed solution A;

[0011] S2. Take another 3-5 parts of glucomannan and mix it with an alkaline compound, then add it to the mixed solution A under rapid stirring and mix well, and keep warm at 85-95°C for not less than 60 minutes; when the glucomannan and the alkaline compound are mixed and added to the mixed solution A, the total amount after mixing is counted as 100 parts;

[0012] S3. Then, it is prepared through low-temperature freezing, mechanical crushing, rinsing and dehydration, placed in a zinc compound solution with a mass concentration of not less than 3%, stirred for not less than 60 minutes, cooled and filtered, then placed in a phosphate compound solution with a mass concentration of not less than 3% and stirred for not less than 60 minutes, washed with water, filtered, dried and pulverized.

[0013] In the preparation method of this phosphoric acid complex, the common raw materials used are easy to operate in the production preparation method, and the production efficiency is high, which is suitable for large-scale production.

[0014] Preferably, the amino-rich compound is one or several combinations of alkaline compounds containing multiple amino groups.

[0015] Preferably, the amino-rich compound is any one of chitosan, polylysine, and polyarginine.

[0016] Preferably, the acid salt compound is a monovalent metal salt of orthophosphate or / and polycondensed phosphate.

[0017] Preferably, the phosphate compound is one or several combinations of sodium phosphate, potassium dihydrogen phosphate, sodium tripolyphosphate, sodium pyrophosphate, and sodium hexametaphosphate.

[0018] Preferably, the zinc compound solution is a solution of a mixture of one or several of zinc chloride solution, zinc gluconate solution, zinc glycyrrhizinate solution, zinc acetate solution, zinc citrate solution, and zinc lactate solution.

[0019] Preferably, the alkaline compound is a monovalent metal alkaline compound.

[0020] Preferably, the alkaline compound is one or several combinations of sodium carbonate, sodium bicarbonate, sodium hydroxide, and potassium hydroxide.

[0021] An intestinal anti-bacterial adhesion phosphoric acid complex is obtained by the preparation method of the intestinal anti-bacterial adhesion phosphoric acid complex described above.

[0022] The inventors' research found that when the phosphate concentration reaches 0.05 mol / L or more, both the proliferation of bacteria and the function of outer membrane proteins are significantly inhibited. It may be that the high-phosphate environment affects the phosphorylation process of proteins, changes the hydrophobic properties of protein fragments, and the hydrophobic fragments of proteins have been proven to be the key fragments for adhering to the intestinal mucosa.

[0023] Based on the above conclusions, the use of the phosphate complex for anti-bacterial adhesion in the intestine is to release phosphate in the intestine, increase the phosphate concentration in the intestinal bacterial microenvironment, inhibit the process of outer membrane protein-mediated adhesion to the intestinal mucosa, and play an effective role in anti-bacterial adhesion in the intestine.

[0024] At the same time, in order to construct a phosphate complex rich in phosphate, when preparing the phosphate complex, amino groups (positively charged) of amino-rich compounds such as polylysine and chitosan are selected as carriers of phosphate. At the same time, amino acids and the like (negatively charged groups) in the amino-rich compounds adsorb zinc ions, and zinc ions are used as ionic bridges to bind phosphate, greatly enhancing the phosphate loading capacity of the compound.

[0025] To prevent the phosphate carrier from being absorbed in the small intestine, when preparing the phosphate complex, glucomannan molecules are selected and crosslinked to form a three-dimensional network, and the amino compound-Zn-phosphate molecules are coated in the three-dimensional network to form a phosphate complex.

[0026] To avoid the inhibition of the crosslinking entanglement of glucomannan molecules by the charges of amino-rich compounds and zinc ions, when preparing the phosphate complex, the amino compound is first charge-neutralized and shielded with a phosphate compound, zinc ion replacement is carried out after the crosslinking process, and then phosphate is loaded onto the zinc ions again to increase the amount of phosphate in the complex. Finally, it is washed once with water to wash away the unloaded free phosphate.

[0027] To coat the amino-rich molecules in the glucomannan molecular network, when preparing the phosphate complex, the acetyl groups of some glucomannan molecules are creatively used to first combine with the amino groups of the amino-rich molecules (forming hydrogen bonds), and then coating and crosslinking are carried out, solving the technical problem that it is difficult to fix amino-rich molecular compounds lacking branched chains.

[0028] An application of a phosphate complex for anti-bacterial adhesion in the intestine, the application of the phosphate complex in the preparation of functional foods or pharmaceutical products for preventing and treating intestinal health problems.

[0029] Compared with the prior art, the present invention has at least the following technical effects:

[0030] The present invention provides a phosphoric acid complex for anti-bacterial adhesion in the intestine. The phosphoric acid complex is prepared from an amino-rich compound, a solution of a phosphate compound with a mass concentration of 3% or more, a solution of a zinc compound with a mass concentration of 3% or more, glucomannan, an alkaline solution, and water. The phosphoric acid complex can effectively inhibit the adhesion of bacteria to the intestinal mucosa, control the probability of intestinal bacteria invasion, reduce the occurrence rate of intestinal leakage, control chronic inflammation in the body, solve the intestinal health problems caused by intestinal bacteria adhesion, and has an important role.

[0031] The phosphoric acid complex has the following advantages:

[0032] (1) By increasing the local phosphate concentration in the intestinal lumen, the purpose of effectively inhibiting bacterial adhesion in the intestinal lumen is achieved;

[0033] (2) Creatively select an amino-rich compound and zinc as phosphate carriers, use the acetyl groups of glucomannan molecules to bind to the amino-rich compound, and coat the phosphate carriers in the three-dimensional network of polysaccharide molecules through the cross-linking and entanglement of glucomannan molecules to prevent the absorption of phosphate in the small intestine;

[0034] (3) Creatively select a phosphate compound to shield the charge of the amino-rich compound, separate the replacement of zinc ions from the glucomannan molecule cross-linking process, and effectively prevent the interference of charge on the glucomannan molecule cross-linking.

[0035] (4) To ensure the safety of the product, no reagents and substances harmful to health are introduced. The preparation process used is simple and easy to scale up industrially, avoiding the generation of harmful substances during the production process, being easy to operate, and enabling large-scale production.

[0036] (5) The phosphoric acid complex for anti-bacterial adhesion in the intestine can effectively inhibit the adhesion of intestinal bacteria and can be used as a functional food or pharmaceutical product for preventing and treating intestinal health problems. Description of the Drawings

[0037] Figure 1 The research sample of KGM / PLL / PI prepared in Example 1. Detailed Embodiments

[0038] The following will describe the embodiments of the present invention in detail in combination with the examples. However, those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention. The specific conditions not specified in the examples are carried out according to the conventional conditions or the conditions recommended by the manufacturer. The reagents or instruments not specified for the manufacturer can be obtained as conventional products through commercial purchase.

[0039] Example 1:

[0040] A preparation method of an intestinal anti-bacterial adhesion phospho-complex, comprising the following preparation steps:

[0041] S1. Dissolve 2 kg of polylysine, 1 kg of sodium pyrophosphate, and 0.3 kg of glucomannan in 92.7 kg of water, stir, and keep at 80 °C for 30 min to prepare Solution A.

[0042] S2. Take 4 kg of glucomannan and 0.3 kg of sodium bicarbonate, mix them evenly, and add them to Solution A under rapid stirring, then keep at 90 °C for 60 min.

[0043] S3. Then, through low-temperature freezing, mechanical crushing, rinsing and dehydration, place it in a zinc chloride solution with a mass concentration of 4% and stir for 60 min, cool and filter, then place it in a sodium phosphate solution with a mass concentration of 4% and stir for 60 min, wash with water, filter, dry and pulverize to prepare the intestinal anti-bacterial adhesion phospho-complex.

[0044] Example 2:

[0045] A preparation method of an intestinal anti-bacterial adhesion phospho-complex, comprising the following preparation steps:

[0046] S1. Dissolve 1 kg of chitosan, 0.3 kg of sodium phosphate, 0.2 kg of potassium dihydrogen phosphate, and 0.1 kg of glucomannan in 95.2 kg of water, stir, and keep at 85 °C for 50 min to prepare Solution A.

[0047] S2. Take 3 kg of glucomannan and 0.1 kg of potassium hydroxide, mix them evenly, and add them to Solution A under rapid stirring, then keep at 85 °C for 90 min.

[0048] S3. Then, through low-temperature freezing, mechanical crushing, rinsing and dehydration, place it in a solution containing 1% zinc gluconate + 1% zinc glycyrrhizinate + 1% zinc acetate by mass concentration and stir for 120 min, cool and filter, then place it in a solution containing 1% sodium tripolyphosphate + 2% sodium pyrophosphate by mass concentration and stir for 90 min, wash with water, filter, dry and pulverize to prepare the intestinal anti-bacterial adhesion phospho-complex.

[0049] Example 3:

[0050] A preparation method of an intestinal anti-bacterial adhesion phospho-complex, comprising the following preparation steps:

[0051] S1. Dissolve 1 kg of chitosan, 2 kg of polylysine, 1 kg of sodium tripolyphosphate, 1 kg of sodium hexametaphosphate, and 0.5 kg of glucomannan in 88.7 kg of water, stir, and keep at 70 °C for 120 min to prepare Solution A.

[0052] S2. Take 5 kg of glucomannan, 0.4 kg of sodium carbonate and 0.1 kg of sodium bicarbonate, mix them evenly, and add them to Solution A under rapid stirring, then keep it at 95 °C for 60 min.

[0053] S3. Then, it is subjected to low-temperature freezing, mechanical crushing, rinsing and dehydration, placed in a solution containing 1% zinc glycinate + 1% zinc acetate + 0.5% zinc citrate + 1% zinc lactate and stirred for 90 min, cooled and filtered, then placed in a solution containing 1% potassium dihydrogen phosphate + 2% sodium tripolyphosphate + 1% sodium pyrophosphate + 0.5% sodium hexametaphosphate and stirred for 60 min, washed with water, filtered, dried and pulverized to prepare an intestinal anti-bacterial adhesion phosphate complex.

[0054] Example 4:

[0055] A preparation method of an intestinal anti-bacterial adhesion phosphate complex, comprising the following preparation steps:

[0056] S1. Dissolve 0.5 kg of chitosan, 0.5 kg of polylysine, 1.5 kg of polyarginine, 0.2 kg of sodium phosphate, 0.2 kg of potassium dihydrogen phosphate, 0.2 kg of sodium tripolyphosphate, 0.2 kg of sodium pyrophosphate, 0.7 kg of sodium hexametaphosphate and 0.2 kg of glucomannan in 92.2 kg of water, stir and keep it at 95 °C for 30 min to prepare Solution A.

[0057] S2. Take 3.5 kg of glucomannan, 0.1 kg of sodium carbonate, 0.1 kg of sodium bicarbonate, 0.1 kg of sodium hydroxide and 0.1 kg of potassium hydroxide, mix them evenly, and add them to Solution A under rapid stirring, then keep it at 88 °C for 60 min.

[0058] S3. Then, it is subjected to low-temperature freezing, mechanical crushing, rinsing and dehydration, placed in a solution containing 5% zinc chloride + 2% zinc citrate + 0.3% zinc lactate and stirred for 60 min, cooled and filtered, then placed in an 8% sodium tripolyphosphate solution and stirred for 60 min, washed with water, filtered, dried and pulverized to prepare an intestinal anti-bacterial adhesion phosphate complex.

[0059] Setting of comparative examples:

[0060] For further illustration and comparison, by changing the component ratio or process flow parameters of the present invention, the products prepared all have defects, as shown in Table 1 below:

[0061]

[0062]

[0063] Test example: Take the complexes prepared in each example and comparative example and conduct relevant performance measurements.

[0064] 1. Determination of bacterial adhesion inhibition rate:

[0065] 1.1 Preparation of bacterial suspension: Take the overnight cultured Salmonella typhi Ty21a bacterial suspension, inoculate it into a new test tube containing LB broth, culture it in a shaker at 37 °C and 170 r / min for 9 h, measure the OD value of the bacterial suspension at 655 nm using an enzyme-linked immunosorbent assay (ELISA) reader, calculate the cell concentration according to the standard curve of bacterial concentration and absorbance value, centrifuge the bacterial suspension at 12000 r / min for 2 min, discard the supernatant, wash it twice with PBS, and finally dilute it with PBS to 10 9 CFU / mL for the bacterial adhesion test.

[0066] 1.2 Preparation of porcine intestinal epithelial cells (IPEC-J2): Take out the cell cryopreservation tube from liquid nitrogen, warm it in a 37 °C water bath, shake the cryopreservation tube continuously during the process to accelerate melting. After melting, add 10 mL of complete medium (10% fetal bovine serum + 10 ng / mL EGF + 1% penicillin-streptomycin + DMEM F12), centrifuge at 1000 r / min for 5 min, discard the supernatant, resuspend it with complete medium, gently pipette and mix well, inoculate it into a 75 cm 2 culture flask, culture it in an incubator at 37 °C and 5% CO2, and change the medium every other day. Passage can be carried out when the cells grow to 80%-90%. Take out the cell culture flask, wash it twice with PBS, mix trypsin and PBS at a volume ratio of 2:1, add it to the cell flask, put it in the incubator for digestion for 8-10 min. After complete digestion, terminate the digestion with an equal volume of complete medium, centrifuge to remove trypsin, resuspend it with complete medium, count the cell concentration using a hemocytometer, adjust the cells to 2×10 5 cells / mL, inoculate it into a 24-well plate, 0.5 mL per well, and the experiment can be carried out when the cells grow to a monolayer.

[0067] 1.3 Anti-bacterial adhesion test: Wash the cells that have grown to a monolayer twice with PBS, then add 60 μL (10 9 CFU / mL) of the above-diluted bacterial suspension, PBS (control), or 0.1 g of the inventive sample material (example or comparative example material) to the cell wells respectively, put them in the incubator for incubation for 45 min, take them out, aspirate the liquid, wash the cells twice with PBS to wash away the example or comparative example material and unadhered bacteria. Then add 400 μL of sterilized ultrapure water to each well, and then put the cells in the incubator for culture for 30 min to rupture the cell membrane and release the bacteria. Then add 600 μL of PBS to each well, and dilute it 2000 times with sterilized normal saline, and count on an LB plate, with 2 parallels for each sample.

[0068] Formulas for calculating bacterial adhesion rate and adhesion inhibition rate:

[0069] Bacterial adhesion rate = (number of bacteria released from cells / number of bacteria added) × 100%

[0070] Bacterial adhesion inhibition rate (%) = (bacterial adhesion rate of control group - bacterial adhesion rate of sample) / bacterial adhesion rate of control group × 100%

[0071] The measurement results are shown in Table 2.

[0072] Table 2 Measurement results of bacterial adhesion inhibition rate (%)

[0073] Sample Adhesion inhibition rate Sample Adhesion inhibition rate Sample Adhesion inhibition rate Control group 0％ Comparative example 5 2.1％ Comparative example 17 22.5％ Example 1 88.3％ Comparative example 7 11.7％ Comparative example 18 26.7％ Example 2 85.5％ Comparative example 9 14.8％ Comparative example 19 18.3％ Example 3 89.6％ Comparative example 11 17.2％ Comparative example 21 10.5％ Example 4 85.1％ Comparative example 13 18.4％ Comparative example 22 9.4％ Comparative example 1 1.2％ Comparative example 14 21.3％ Comparative example 24 17.0％ Comparative example 2 1.4％ Comparative example 15 26.2％ Comparative example 25 15.6％ Comparative example 4 1.1％ Comparative example 16 1.4％ Comparative example 26 13.3％

[0074] As can be seen from Table 2, the products prepared in each example have a bacterial adhesion inhibition rate as high as over 80%, while the anti-adhesion effects of the comparative examples are all relatively low.

[0075] 2. Research on anti-Salmonella typhimurium infection

[0076] 2.1 Preparation of streptomycin-resistant Salmonella typhimurium suspension: Use an inoculation loop to pick Salmonella typhimurium CMC50013 and streak it on an LB agar plate containing 50 μg / mL streptomycin, and place it in a 37°C biochemical incubator. After culturing for about 24 h, single colonies grow. Pick a single colony and inoculate it into an LB medium containing 50 μg / mL streptomycin, and place it in a 37°C constant temperature shaker and shake it at 250 rpm for 18 h until the bacterial solution becomes turbid. Take 30 μL of the bacterial solution and transfer it to 3 mL of LB medium containing 50 μg / mL streptomycin, and place it in a 37°C constant temperature shaker and shake it at 250 rpm for 18 h until the bacterial solution becomes turbid. Take 70 μL of the bacterial solution and transfer it to 7 mL of LB medium containing 50 μg / mL streptomycin, and place it in a 37°C constant temperature shaker and shake it at 250 rpm for 2.5 h. Use a spectrophotometer to measure the absorbance OD600 of the bacterial solution to be about 0.5, and the bacterial concentration is about 3×10 8 CFU / mL. Centrifuge at 5000 rpm for about 3 min, discard the supernatant, add 2.1 mL of sterile phosphate buffer PBS, and each 100 μL of the bacterial suspension contains about 1×10 8 CFU of Salmonella typhi.

[0077] 2.2 Select 35 male C57 / BL6 mice at 5 - 6 weeks of age with a body weight of 17 - 19 g. Set the room temperature at 22°C and raise them under a 12 - hour light - dark cycle for 1 week. Randomly divide them into 7 groups (n = 5), namely a normal control group, an infection model group, and treatment groups (Examples 1 - 4, comparative examples). The experimental period is 7 days. One day before the start of the experiment, each group of mice drinks pure water containing 5 g / L streptomycin. After 24 hours, change back to normal drinking water. During the experimental period from day 1 to day 7, each group of mice is gavaged with 100 μL at a fixed time every morning (the normal group is gavaged with phosphate - buffered saline PBS, the infection group is gavaged with Salmonella typhi, and the treatment groups of Examples are gavaged with Salmonella + 0.1 g of the materials of Examples 1 - 4). The mice with bacteria and the germ - free mice are raised and operated in isolation. On the 7th day of the experiment, 5 fresh feces are taken from each group of mice. Each fecal pellet is weighed and placed in a 1.5 - mL centrifuge tube for bacterial counting. The mice are sacrificed by cervical dislocation, soaked in 75% alcohol for 30 s, dissected along the mid - abdominal line, and the entire liver and spleen are taken out with sterilized instruments and immediately placed in a sterile petri dish for bacterial counting.

[0078] 2.3 Bacterial counting: Add 1 mL of PBS to each tube of feces and homogenize. Take 0.1 mL of the fecal homogenate and spread it on a Salmonella identification plate (bismuth sulfite agar disposable plate). After incubation at 37°C for 24 - 36 h, count the colonies, and calculate the actual number of Salmonella in each gram of feces according to the weight. During the process of the bacterial translocation experiment, strict aseptic control is carried out. After the liver and spleen are taken out of the mice, they are immediately rinsed with physiological saline, dried with filter paper and weighed. Take 0.1 g of tissue (from the same part) and put it into a pre - cooled 1.5 - mL centrifuge tube containing 1 mL of PBS for grinding. Take 0.1 mL of the tissue homogenate and spread it on an LB agar culture plate. After incubation at 37°C for 18 - 24 h, count the colonies, and calculate the actual number of Salmonella in each gram of tissue according to the weight.

[0079] The research results are shown in Table 3.

[0080] Table 3 Bacterial counts in feces and bacterial translocation in the liver and spleen of mice (n = 5) on the 7th day of the experiment

[0081]

[0082]

[0083] As can be seen from Table 3, compared with the infection group, the fecal bacterial count and bacterial translocation in the spleen and liver of the 18th comparative example group are reduced, but the reduction degree is far less than that of Examples 1 - 4, indicating that the materials of the present invention can effectively reduce the adhesion, colonization and invasion of Salmonella.

[0084] Finally, it should be noted that the above are only the preferred embodiments of the present invention and are not intended to limit the protection scope of the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.

Claims

1. A method for preparing a phosphoric acid complex with anti-bacterial adhesion to the intestine, characterized in that, It includes the following steps: S1. Select 1 - 3 parts of amino - rich compounds, 0.5 - 2 parts of phosphate compounds, and 0.1 - 0.5 part of glucomannan, mix them together and dissolve in water, stir and keep warm at 70 - 95 °C for no less than 30 min to obtain mixture A; S2. Take another 3 - 5 parts of glucomannan and an alkaline compound, mix them evenly, and add them to mixture A under rapid stirring and mix well, then keep warm at 85 - 95 °C for no less than 60 min; the total amount after mixing the glucomannan and the alkaline compound added to mixture A is counted as 100 parts; S3. Then, it is prepared by low - temperature freezing, mechanical crushing, rinsing and dehydration, placing it in a zinc - containing compound solution with a mass concentration of not less than 3%, stirring for no less than 60 min, cooling and filtering, then placing it in a phosphate - containing compound solution with a mass concentration of not less than 3% and stirring for no less than 60 min, washing, filtering, drying and pulverizing.

2. The preparation method of a phosphoric acid complex for intestinal anti-bacterial adhesion according to claim 1, characterized in that, The amino - rich compound is one or several combinations of basic compounds containing multiple amino groups.

3. The preparation method of a phosphoric acid complex for intestinal anti-bacterial adhesion according to claim 2, wherein, The amino - rich compound is any one of chitosan, polylysine, and polyarginine.

4. The preparation method of a phosphoric acid complex for intestinal anti-bacterial adhesion according to claim 1, characterized in that, The acid salt compound is a monovalent metal salt of orthophosphate or / and condensed phosphate.

5. The preparation method of a phosphoric acid complex for intestinal anti-bacterial adhesion according to claim 4, characterized in that, The phosphate compound is one or several combinations of sodium phosphate, potassium dihydrogen phosphate, sodium tripolyphosphate, sodium pyrophosphate, and sodium hexametaphosphate.

6. The preparation method of a phosphoric acid complex for intestinal anti-bacterial adhesion according to claim 1, characterized in that, The zinc - containing compound solution is a solution of one or several mixtures of zinc chloride solution, zinc gluconate solution, zinc glycyrrhizinate solution, zinc acetate solution, zinc citrate solution, and zinc lactate solution.

7. A method for preparing a phosphoric acid complex for intestinal anti-bacterial adhesion according to claim 1, characterized in that, The alkaline compound is a monovalent metal alkaline compound.

8. The preparation method of a phosphoric acid complex for intestinal anti-bacterial adhesion according to claim 7, characterized in that, The alkaline compound is one or several combinations of sodium carbonate, sodium bicarbonate, sodium hydroxide, and potassium hydroxide.

9. A phosphoric acid complex for anti-bacterial adhesion in the intestine, characterized in that, Obtained by the preparation method of the phosphoric acid complex with antibacterial adhesion to the intestine according to any one of claims 1 - 8.

10. Use of a phosphoric acid complex for anti-bacterial adhesion in the intestine as described in claim 9, characterized in that, The application of the phosphoric acid complex in the preparation of functional foods or pharmaceutical products for preventing and treating intestinal health problems.

Images